MANHASETT, N.Y.–(BUSINESS WIRE)–January 12, 2023–
Almost everyone who develops a high-grade glioma will have the tumor regrow at some point, even after surgery, chemotherapy, or radiation therapy. To harness the potential of non-invasive ultrasound technology, clinicians at Northwell Health and clinical trial researchers at the Feinstein Institutes for Medical Research have begun participating in Alpheus™ Medical, Inc’s Phase 1 clinical trial. , the first group of patients at North Shore University Hospital (NSUH).
This press release features multimedia. Read the full release here: https://www.businesswire.com/news/home/20230112005272/en/
Yehuda Haber (left) talks with Dr. Michael Schulder about Alpheus Medical’s ultrasound clinical trial. (Credit: The Feinstein Institute)
For many patients diagnosed with high-grade gliomas, including glioblastoma, there are few therapeutic options to treat these relapses. This multi-site clinical trial aims to study the safety and optimal dosage of a new investigational sonodynamic therapy (SDT) platform that targets solid tumors via ultrasound.
said Michael Schulder, M.D., Ph.D., professor of molecular medicine at The Feinstein Institute and director of the Brain Tumor Center at the Institute of Neurology and Neurosurgery at Northwell Health. Principal investigator of clinical trials. “We are eager to make this new clinical trial available to participants and thank you for your participation so that we can research this potentially beneficial treatment.”
Yehuda Haber, 62, was one of the first patients to be enrolled and treated in the trial at NSUH and the first patient with his type of brain tumor. Diagnosed with oligodendroglioma 20 years ago, his Mr. Haber, a former Israeli Navy SEAL, was treated with radiation and oral chemotherapy. Three years ago he was referred to his Dr. Schulder for treatment with Laser Interstitial Thermotherapy (LITT), a revolutionary technique for treating small tumor growths. He has had these procedures four times, and they have all been successful. However, Dr. Schulder advised that LITT alone is not a long-term solution. On Oct. 12, Haber enrolled in his Alpheus clinical trial, which is intended to treat whole tumors.
“I never thought my brain tumor would come back, but when it did, I knew I didn’t want to go through painful radiation or chemotherapy again,” Haber said. When he told me about the exam, I didn’t hesitate to sign up and I hope this treatment will help me and others who are fighting for their lives. Nothing!
A noninvasive drug-device combination treatment uses low-intensity, wide-field ultrasound to target cancer cells throughout the brain hemispheres. The method can be performed in an outpatient setting, allows for repeated applications, and does not require imaging during the session. The trial will enroll up to 33 patients with high-grade gliomas, including glioblastoma, at his three sites nationwide.
“Clinical trials to assess safety and efficacy are an important step before a new medical technology becomes widely used,” said Karches Family, president and CEO of the Feinstein Institute for Medical Research. said Kevin J. Tracey, MD, Distinguished Chair in Medical Research. “Dr. Schulder’s clinical studies of brain tumors are generating important new knowledge to guide future therapeutic strategies.”
Alpheus Medical is the study sponsor. For more information, please visit www.clinicaltrials.gov/ct2/show/NCT05362409.
About The Feinstein Laboratories
Feinstein Institute of Medicineis home to the research institutes of Northwell Health, New York State’s largest healthcare provider and private employer. With 50 laboratories, 3,000 clinical studies, and 5,000 researchers and staff, the Feinstein Institutes set the bar for medical innovation through five laboratories: Behavioral Sciences, Bioelectronics, Oncology, Health Systems Sciences, and Molecular Medicine. pulling up. We are a global scientific leader in bioelectronic medicine, a new scientific field with the potential to revolutionize medicine, achieving breakthroughs in genetics, oncology, brain research, mental health, and autoimmunity. Leader. For more information on how to generate knowledge to cure disease, please visit:http://feinstein.northwell.eduand follow usLinkedIn.
View source version at businesswire.com: https://www.businesswire.com/news/home/20230112005272/en/
Contact: Matthew Ribassi
631-793-5325
mlibassi@northwell.edu
Keywords: United States North America New York
Industry Keywords: Oncology Health Clinical Trials Research Pharmacy
Source: The Feinstein Institute of Medicine
Copyright Business Wire 2023.
Published: Jan 12, 2023 10:00 AM / Disc: Jan 12, 2023 10:03 AM
http://www.businesswire.com/news/home/20230112005272/en
Copyright Business Wire 2023.
